Navigation Links
PMDA Approves Jarvik 2000 Heart in Japan
Date:12/5/2013

NEW YORK, Dec. 5, 2013 /PRNewswire/ -- JARVIK HEART, Inc., a privately-held company that develops and manufactures cardiac assist devices, announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has granted approval to the Shonin (or pre-market approval) application submitted by Century Medical, Inc., (CMI) for the Jarvik 2000 Heart, a small Left Ventricular Assist Device (LVAD) implanted inside the natural heart. CMI is the exclusive distributor of the Jarvik 2000 in Japan. Shonin approval was granted on November 22, 2013, following the PMDA's review of data on Japanese and U.S. clinical trials with the device. In Japan, where there is an extended waiting time for donors, patients have been supported long term by the Jarvik 2000, for up to four years, and then have been successfully transplanted  once a donor heart has become available.

The Jarvik 2000, manufactured in New York by Jarvik Heart, Inc., is the smallest LVAD approved for long-term use in Japan. At only 30cc volume and 90 grams (about the size of a C-cell battery), the Jarvik 2000 can support the hearts of patients only 4' 6" tall and weighing less than 85 lbs. Yet the same blood pump can also support large patients more than 6' 2" tall and weighing more than 225 lbs. For smaller patients, the pump is operated at slower speeds; for larger patients, it is operated at higher speeds.

In Europe, the Jarvik 2000 Heart has CE mark approval. In the U.S., Jarvik Heart has completed a 150-patient Pivotal Trial for Bridge to Transplant. A randomized trial (with comparison to the HeartMate II) for long-term use is currently in progress. More than 300 patients will be evaluated for survival two years after implant and for absence of infection at three years. 

More than 600 patients at dozens of hospitals in twelve countries have been treated for severe heart failure with the Jarvik 2000. Many patients have been transplanted or supported long term with an excellent quality of life. Today (Dec. 5th), a patient in France celebrates his eighth year of active life supported by the Jarvik 2000. The very first patient to receive the Jarvik 2000 as a bridge to a transplant is doing well thirteen years after implantation of her donor heart.

Jarvik Heart, Inc. is also developing a miniature Jarvik 2000 for use in infants. This work is supported by the National Heart, Lung, and Blood Institute (NHLBI) under the PumpKIN program (Pumps for Kids, Infants, and Neonates). Initiation of a multicenter clinical trial is planned for 2014.

For more information, please visit jarvikheart.com and cmi.co.jp.


'/>"/>
SOURCE Jarvik Heart, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
2. FDA Approves NDA Supported By MedAvante Central Ratings
3. Cardinal Health Board Of Directors Approves Cash Dividend; Authorizes New $750 Million Share Repurchase Program
4. FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
5. Specialty Pharmacy Certification Board (SPCB) Approves Content for Certified Specialty Pharmacist (CSP) Certification Exam
6. FDA APPROVES APTIMA HPV ASSAY FOR USE ON HOLOGICS PANTHER SYSTEM
7. FDA Approves Epaned, a Liquid Form of Enalapril for Children and Adults
8. FDA approves drug tested by Scottsdale Healthcare and TGen
9. FDA Approves Aptima HPV 16 18/45 Genotype Assay for Use on Hologics Panther System
10. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
11. Retired Pro Hockey Player 1st to Receive Total Artificial Heart in Upstate New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , January 20, 2017 Avillion LLP, ... appointment of Mark Weinberg , MD MBA as Chief Medical ... , USA . ... Dr Weinberg has spent more than 17 years ... 20" pharma companies to micro-cap biotech. Over the course of his ...
(Date:1/19/2017)... The Global Therapy Partnering Terms and Agreements ... deals and agreements entered into by the world,s leading ... Top deals by value - Deals listed by company ... The report provides understanding and access to the partnering ... healthcare companies. The report provides an analysis of ...
(Date:1/19/2017)... Jan. 19, 2017 This report on the ... future scenario of the global market. Large number of ... Severe chronic constipation is a major side effect of ... Hence, novel targeted therapy has been prescribed to treat ... of targeted medicines, and growing awareness about the therapy ...
Breaking Medicine Technology:
(Date:1/20/2017)... Texas (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... the bible in homes across the world. Yisrayl says this generation is a time like ... is to turn to the Bible. , Yisrayl says he does not want to sound ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Lice Troopers, the ... cases in families with school-aged children since the holiday season. , “It happens ... with their families, sharing hugs and taking photos, which is the head-to-head gateway that ...
(Date:1/20/2017)... ... ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that are fully ... - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains 44 lens ... and light leak transitions have a very high-dynamic range for super smooth falloff. Simply ...
(Date:1/20/2017)... ... 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went on ... of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age of ... 19 years of age, he joined the Navy and got married right out of boot ...
(Date:1/20/2017)... ... 20, 2017 , ... “Journey to Christmas:” a beautiful and enchanting tale that teaches children the ... a mother of three in Oklahoma City, and a devoted woman of faith. , ... has been in the back of my mind for years, but actually doing it might ...
Breaking Medicine News(10 mins):